Inhibrx, Inc. (INBX) AI Stock Analysis

Inhibrx, Inc., based in La Jolla, California, is a clinical-stage biotechnology firm dedicated to advancing biologic therapeutic candidates. Its pipeline includes INBRX-109, a tetravalent agonist targeting death receptor 5 in Phase 2 clinical trials for chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma. The company is also evaluating INBRX-105, a tetravalent conditional agonist of PD-L1 and 4-1BB, in Phase 1 trials for locally advanced or metastatic solid tumors. Additionally, Inhibrx is advancing INBRX-101, an AAT-Fc fusion protein therapeutic in Phase 1 for alpha-1 antitrypsin deficiency, alongside INBRX-106, a hexavalent agonist targeting OX40 for multiple oncology indications.

Inhibrx generated $0 in trailing twelve months revenue through June 30, 2026, with quarterly revenue growth falling 100.0% year-over-year. In FY2025, revenue increased 550.0% to $1.3M from $200,000 in FY2024, though down from $1.8M in FY2023, $2.2M in FY2022, and $7.1M in FY2021. This reflects a 5-year revenue CAGR of -36.7% from FY2020 to FY2025. In FY2025, operating margin was -10386.5%, net margin was -10773.5%, and net income was -$140.1M, with an EPS of -$9.04. Research and development expenses were $113.0M in FY2025, down from $203.7M in FY2024.

As of June 30, 2026, Inhibrx held $133.3M in cash and short-term investments against total debt of $5.3M, leaving net cash of $128.0M. Total assets stood at $154.2M, while shareholders' equity was -$53.0M. The company had a current ratio of 5.07. Operating cash flow in FY2025 was -$129.8M, matching a free cash flow deficit of -$129.8M alongside capital expenditures of $31,000.

At a last close of $89.83 on October 16, 2026, Inhibrx had a market capitalization of $1.32B and an enterprise value of $1.53B. The stock traded at a price-to-book multiple of 212.3x and an EV/EBITDA of 0.0x, compared to the median EV/EBITDA of 12.0x for its US-listed Healthcare peers. Over the past year, INBX delivered a 145.5% return, outperforming the S&P 500 (SPY) return of 16.8%.

Wall Street coverage includes 3 Strong Buy ratings and 1 Hold rating. The mean price target is $266.67, representing a 196.9% upside compared to the last close of $89.83. For the fiscal year ending December 31, 2026, analysts expect $0 in revenue and an EPS of -$9.26. For the next fiscal year, 2 analysts project revenue of $36.1M and an EPS of -$8.76. Inhibrx beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 13, 2026.

This page is an AI-written research summary of Inhibrx, Inc. (INBX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: INBX income statement, INBX balance sheet, INBX key metrics, INBX analyst forecast, INBX chart. See the INBX stock overview for the latest quote and news.